PEDIATRIC LATE OUTCOMES PROTOCOL ACTG 219C

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者的研究机构。 ACTG 219c 本研究的目的是跟踪所有在儿科艾滋病临床试验组（Pediatric AIDS Clinical Trials Group）站点就诊的婴儿、儿童和青少年，以及怀孕时参加PACTG药物研究的HIV感染母亲所生的婴儿，以寻找所服用药物或疫苗的长期益处或任何晚期有害影响。所有儿童都有资格被跟踪到至少24岁生日。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. ACTG 219c The purpose of this study is to follow all infants, childern and adolescents who are seen at Pediatric AIDS Clinical Trials Group sites as well as infants born to HIV-infected mothers who were enrolled in a PACTG drug study when they were pregnant, to look for long-term benefits or any late, harmful effects of medications or vaccines taken. All childern are eligible to be followed until at least their 24th birthday.